Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Acquisitions (2018 - 2022)

Collegium Pharmaceutical has reported Acquisitions over the past 2 years, most recently at $572.1 million for Q1 2022.

  • Quarterly results put Acquisitions at $572.1 million for Q1 2022, changed N/A from a year ago — trailing twelve months through Dec 2022 was $572.1 million (changed N/A YoY), and the annual figure for FY2024 was $267.5 million, changed.
  • Acquisitions for Q1 2022 was $572.1 million at Collegium Pharmaceutical, up from $116000.0 in the prior quarter.
  • Over the last five years, Acquisitions for COLL hit a ceiling of $572.1 million in Q1 2022 and a floor of $116000.0 in Q2 2018.